vs

Side-by-side financial comparison of PHIBRO ANIMAL HEALTH CORP (PAHC) and STARWOOD PROPERTY TRUST, INC. (STWD). Click either name above to swap in a different company.

STARWOOD PROPERTY TRUST, INC. is the larger business by last-quarter revenue ($492.9M vs $373.9M, roughly 1.3× PHIBRO ANIMAL HEALTH CORP). STARWOOD PROPERTY TRUST, INC. runs the higher net margin — 19.7% vs 7.3%, a 12.3% gap on every dollar of revenue. On growth, PHIBRO ANIMAL HEALTH CORP posted the faster year-over-year revenue change (20.9% vs 8.5%). Over the past eight quarters, PHIBRO ANIMAL HEALTH CORP's revenue compounded faster (19.2% CAGR vs -2.9%).

Phibro Animal Health Corporation is an American animal health and mineral nutrition company. Its products include antibacterials, anticoccidials, anthelmintics, as well as animal nutrition and vaccines for livestock. The company operates through three segments Mineral Nutrition, Performance Materials, and Animal Health, from which most of its revenue is derived. The company operates in the United States, Latin America, Canada, Europe, Middle East, Africa, and Asia-Pacific. It is incorporated ...

Starwood Hotels and Resorts Worldwide, Inc. was one of the largest companies that owned, operated, franchised and managed hotels, resorts, spas, residences, and vacation ownership properties. Starwood was founded in 1969 as a real estate investment trust named Hotel Investors Trust. In 1995, it was acquired and reorganized by Barry Sternlicht, who was its chairman until 2005 and founder of the Starwood Capital Group. Starwood had 11 brands and owned, managed, or franchised 1,297 properties co...

PAHC vs STWD — Head-to-Head

Bigger by revenue
STWD
STWD
1.3× larger
STWD
$492.9M
$373.9M
PAHC
Growing faster (revenue YoY)
PAHC
PAHC
+12.4% gap
PAHC
20.9%
8.5%
STWD
Higher net margin
STWD
STWD
12.3% more per $
STWD
19.7%
7.3%
PAHC
Faster 2-yr revenue CAGR
PAHC
PAHC
Annualised
PAHC
19.2%
-2.9%
STWD

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
PAHC
PAHC
STWD
STWD
Revenue
$373.9M
$492.9M
Net Profit
$27.5M
$96.9M
Gross Margin
35.5%
Operating Margin
13.5%
26.6%
Net Margin
7.3%
19.7%
Revenue YoY
20.9%
8.5%
Net Profit YoY
762.1%
87.7%
EPS (diluted)
$0.67
$0.25

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PAHC
PAHC
STWD
STWD
Q4 25
$373.9M
$492.9M
Q3 25
$363.9M
$488.9M
Q2 25
$378.7M
$444.3M
Q1 25
$347.8M
$418.2M
Q4 24
$309.3M
$454.4M
Q3 24
$260.4M
$479.5M
Q2 24
$273.2M
$489.8M
Q1 24
$263.2M
$523.1M
Net Profit
PAHC
PAHC
STWD
STWD
Q4 25
$27.5M
$96.9M
Q3 25
$26.5M
$72.6M
Q2 25
$17.2M
$129.8M
Q1 25
$20.9M
$112.3M
Q4 24
$3.2M
$51.6M
Q3 24
$7.0M
$76.1M
Q2 24
$752.0K
$77.9M
Q1 24
$8.4M
$154.3M
Gross Margin
PAHC
PAHC
STWD
STWD
Q4 25
35.5%
Q3 25
32.9%
Q2 25
29.0%
Q1 25
30.1%
Q4 24
32.9%
Q3 24
32.1%
Q2 24
31.9%
Q1 24
30.2%
Operating Margin
PAHC
PAHC
STWD
STWD
Q4 25
13.5%
26.6%
Q3 25
14.1%
19.1%
Q2 25
8.9%
30.5%
Q1 25
9.6%
28.7%
Q4 24
8.3%
15.1%
Q3 24
6.8%
17.2%
Q2 24
6.7%
19.1%
Q1 24
7.6%
30.8%
Net Margin
PAHC
PAHC
STWD
STWD
Q4 25
7.3%
19.7%
Q3 25
7.3%
14.8%
Q2 25
4.5%
29.2%
Q1 25
6.0%
26.8%
Q4 24
1.0%
11.4%
Q3 24
2.7%
15.9%
Q2 24
0.3%
15.9%
Q1 24
3.2%
29.5%
EPS (diluted)
PAHC
PAHC
STWD
STWD
Q4 25
$0.67
$0.25
Q3 25
$0.65
$0.19
Q2 25
$0.43
$0.38
Q1 25
$0.51
$0.33
Q4 24
$0.08
$0.15
Q3 24
$0.17
$0.23
Q2 24
$0.02
$0.24
Q1 24
$0.21
$0.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PAHC
PAHC
STWD
STWD
Cash + ST InvestmentsLiquidity on hand
$74.5M
$499.5M
Total DebtLower is stronger
$624.2M
Stockholders' EquityBook value
$332.4M
$6.8B
Total Assets
$1.4B
$63.2B
Debt / EquityLower = less leverage
1.88×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PAHC
PAHC
STWD
STWD
Q4 25
$74.5M
$499.5M
Q3 25
$85.3M
$301.1M
Q2 25
$77.0M
$259.9M
Q1 25
$70.4M
$440.6M
Q4 24
$67.1M
$377.8M
Q3 24
$89.8M
$357.9M
Q2 24
$114.6M
$259.3M
Q1 24
$98.7M
$327.4M
Total Debt
PAHC
PAHC
STWD
STWD
Q4 25
$624.2M
Q3 25
$628.0M
Q2 25
$631.7M
Q1 25
$635.4M
Q4 24
$639.1M
Q3 24
$295.2M
Q2 24
$312.1M
Q1 24
Stockholders' Equity
PAHC
PAHC
STWD
STWD
Q4 25
$332.4M
$6.8B
Q3 25
$311.7M
$6.9B
Q2 25
$285.7M
$6.4B
Q1 25
$266.0M
$6.4B
Q4 24
$246.8M
$6.4B
Q3 24
$258.5M
$6.5B
Q2 24
$256.6M
$6.2B
Q1 24
$270.1M
$6.3B
Total Assets
PAHC
PAHC
STWD
STWD
Q4 25
$1.4B
$63.2B
Q3 25
$1.4B
$62.4B
Q2 25
$1.4B
$62.4B
Q1 25
$1.3B
$62.2B
Q4 24
$1.3B
$62.6B
Q3 24
$966.3M
$64.2B
Q2 24
$982.2M
$64.1B
Q1 24
$979.0M
$66.2B
Debt / Equity
PAHC
PAHC
STWD
STWD
Q4 25
1.88×
Q3 25
2.01×
Q2 25
2.21×
Q1 25
2.39×
Q4 24
2.59×
Q3 24
1.14×
Q2 24
1.22×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PAHC
PAHC
STWD
STWD
Operating Cash FlowLast quarter
$19.4M
$488.8M
Free Cash FlowOCF − Capex
$8.3M
FCF MarginFCF / Revenue
2.2%
Capex IntensityCapex / Revenue
3.0%
Cash ConversionOCF / Net Profit
0.70×
5.04×
TTM Free Cash FlowTrailing 4 quarters
$47.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PAHC
PAHC
STWD
STWD
Q4 25
$19.4M
$488.8M
Q3 25
$9.3M
$337.6M
Q2 25
$21.3M
$-87.4M
Q1 25
$43.2M
$238.9M
Q4 24
$3.1M
$295.6M
Q3 24
$12.6M
$241.8M
Q2 24
$28.4M
$53.3M
Q1 24
$11.4M
$55.9M
Free Cash Flow
PAHC
PAHC
STWD
STWD
Q4 25
$8.3M
Q3 25
$-4.5M
Q2 25
$8.1M
Q1 25
$35.4M
Q4 24
$-4.7M
Q3 24
$3.0M
Q2 24
$15.4M
Q1 24
$1.7M
FCF Margin
PAHC
PAHC
STWD
STWD
Q4 25
2.2%
Q3 25
-1.2%
Q2 25
2.1%
Q1 25
10.2%
Q4 24
-1.5%
Q3 24
1.2%
Q2 24
5.6%
Q1 24
0.6%
Capex Intensity
PAHC
PAHC
STWD
STWD
Q4 25
3.0%
Q3 25
3.8%
Q2 25
3.5%
Q1 25
2.2%
Q4 24
2.5%
Q3 24
3.7%
Q2 24
4.8%
Q1 24
3.7%
Cash Conversion
PAHC
PAHC
STWD
STWD
Q4 25
0.70×
5.04×
Q3 25
0.35×
4.65×
Q2 25
1.24×
-0.67×
Q1 25
2.07×
2.13×
Q4 24
0.97×
5.72×
Q3 24
1.81×
3.18×
Q2 24
37.80×
0.68×
Q1 24
1.36×
0.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PAHC
PAHC

Medicated Feed Additives And Others$202.1M54%
Mineral Nutrition$68.9M18%
Nutritional Specialties$50.2M13%
Vaccines$37.6M10%
Performance Products$15.0M4%

STWD
STWD

Commercial And Residential Lending Segment$335.2M68%
Infrastructure Lending Segment$70.3M14%
Property Segment$57.8M12%
Other$29.7M6%

Related Comparisons